Accessibility Menu
Vasamed logo

Vasamed(OTC) VSMD

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0%
+0.00Today
Vasamed last closing stock price
MetricPriceDate
Last closeUSD 0.002024-10-29
Vasamed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002024-07-23
1 month+0%USD 0.002024-07-23
3 month+0%USD 0.002024-07-23
Year to date+0%USD 0.002023-11-07
1 year+0%USD 0.002023-02-21
3 year-99.9%USD 0.002021-10-18
5 year-100%USD 0.032019-10-31
Since inception-100%USD 84.001996-02-14

Vasamed Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.01M

Net Income (TTM)

-$5.61M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-8.11 (Low)

Price

$0.00

Volume

6,666

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 11, 1999

VSMD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vasamed

Vasamed, Inc. specializes in developing, manufacturing, licensing, and distributing products focused on circulatory health management. The company offers innovative solutions that enhance the assessment of vascular conditions, catering to both clinicians and patients.

Products and Services
  • SensiLase PAD-IQ for measuring skin perfusion pressure
  • Advanced Wound Imaging & SmartDraw systems for precise wound measurement
  • PAD-IQ Studycast for secure transmission of diagnostic results
Growth Outlook
  • Continued demand for circulatory health solutions supports revenue potential
  • Expansion of product offerings may enhance market reach
  • Strategic partnerships could drive innovation and growth
Financial Highlights
  • Recent quarterly revenue of 513,127 reflects growth potential
  • Trailing twelve months (TTM) operating income margin at 3.42% indicates operational efficiency
  • Current ratio of 0.98 suggests adequate short-term financial health
AI Generated • Jul 1, 2026

Industry

Healthcare Equipment and Supplies

Headquarters

Eden Prairie, MN 55344, US

VSMD Financials

Key Financial Metrics (TTM)

Gross Margin

-5.01%

Operating Margin

342.08%

Net Income Margin

-352.61%

Return on Equity

315.37%

Return on Capital

766.88%

Return on Assets

-305.46%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.01M

Volume

6.67K

Avg. Volume

0

Financials (TTM)

Gross Profit

$367.25K

Operating Income

$4.63M

EBITDA

-$3.67M

Operating Cash Flow

-$4.48M

Capital Expenditure

-$402.97K

Free Cash Flow

-$4.88M

Cash & ST Invst.

$625.41K

Total Debt

$3.01M

Vasamed Performance Analysis

Vasamed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42005-12-3165.9%
Q12006-03-31-20.2%
Q22006-06-301.5%
Q32006-09-3010.7%
Vasamed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42005-12-3138.1%
Q12006-03-31-23.1%
Q22006-06-30-37.5%
Q32006-09-30-2.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2006YOY CHG

Revenue

$513.13K

+48.8%

Gross Profit

$155.79K

+237.4%

Gross Margin

30.36%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

5

N/A

Net Income

-$1.72M

-8.8%

EBITDA

-$795.17K

+48.5%

Quarterly Fundamentals

Name
Q3 2006YOY CHG

Total Cash

$625.41K

-18.9%

Total Debt

$3.01M

+12340.6%

Accounts Receivable

$323.98K

-0.2%

Inventory

$703.21K

+25.9%

Long Term Debt

$3.00M

+15153.7%

Short Term Debt

$6.57K

+46.0%

Return on Assets

-3.05%

N/A

Return on Invested Capital

7.72%

N/A

Free Cash Flow

-$1.31M

+9.0%

Operating Cash Flow

-$1.23M

+13.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GMVDFG Medical Innovations Holdings Ltd
$0.00+0.00%
ASFXAmerican Scientific Resources, Incorporated
$0.00+0.00%
MDITMedite Cancer Diagnostics, Inc.
$0.00+0.00%
MRRCFWayland Group Corp.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About VSMD

What is the current price of Vasamed?

Vasamed is trading at $0.00 per share.

What is the 52-week range for Vasamed?

Over the past 52 weeks, Vasamed has traded between $0.00 and $0.00.

How much debt does Vasamed have?

Vasamed total debt is unavailable.

How much cash does Vasamed have on hand?

Vasamed does not have cash on hand data available.

What is Vasamed’s dividend yield?

Vasamed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.